Overview
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
Research Report
Gefitinib (DB00317): A Comprehensive Monograph on its Pharmacology, Clinical Utility, and Evolving Role in Precision Oncology
Executive Summary
Gefitinib, marketed under the brand name Iressa®, is an orally active, small molecule therapeutic that represents a foundational achievement in the field of precision oncology.[1] As a first-generation inhibitor of the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase, its development and clinical application have profoundly shaped the modern approach to treating non-small cell lung cancer (NSCLC).[1] The core mechanism of Gefitinib involves the reversible and competitive inhibition of the adenosine triphosphate (ATP) binding site within the EGFR's intracellular kinase domain. This action is particularly potent against tumors driven by specific "activating" mutations, namely exon 19 deletions and the L858R substitution in exon 21, for which Gefitinib demonstrates a significantly higher binding affinity compared to the wild-type receptor.[1]
The primary clinical application of Gefitinib is as a first-line monotherapy for patients with metastatic NSCLC whose tumors harbor these sensitizing EGFR mutations.[4] This targeted indication was definitively established by the landmark Iressa Pan-Asia Study (IPASS), which demonstrated superior progression-free survival (PFS) for Gefitinib over standard chemotherapy in the EGFR-mutated patient population, thereby cementing the role of EGFR mutation status as a critical predictive biomarker.[8] However, the initial efficacy of Gefitinib is invariably limited by the emergence of acquired resistance. The most common resistance mechanism is the development of a secondary "gatekeeper" mutation, T790M, which restores the kinase's affinity for ATP and renders the tumor insensitive to the drug.[1]
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2005/09/15 | Phase 2 | Completed | |||
2005/09/15 | Phase 2 | Terminated | Groupe Oncologie Radiotherapie Tete et Cou | ||
2005/08/30 | Phase 2 | Completed | |||
2005/08/16 | Phase 2 | Completed | |||
2005/08/09 | Phase 1 | Completed | |||
2005/08/04 | Phase 2 | Completed | |||
2005/06/09 | Phase 1 | Completed | |||
2005/03/04 | Not Applicable | Terminated | |||
2005/02/08 | Phase 2 | Completed | |||
2005/01/10 | Phase 2 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
View More Health Canada Approvals
Sign in to access additional Health Canada approved drug information with detailed regulatory data.
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
No Health Canada approvals found for this drug. |
CIMA AEMPS Drug Approvals
View More CIMA AEMPS Approvals
Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
View More Philippines FDA Approvals
Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
View More Saudi SFDA Approvals
Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
View More Malaysia NPRA Approvals
Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
View More UK EMC Drug Information
Sign in to access additional UK EMC drug information with detailed pharmaceutical data.
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.